174 related articles for article (PubMed ID: 35650602)
1. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).
Smilde BJ; Stockklausner C; Keen R; Whittaker A; Bullock AN; von Delft A; van Schoor NM; Yu PB; Eekhoff EMW
BMC Musculoskelet Disord; 2022 Jun; 23(1):519. PubMed ID: 35650602
[TBL] [Abstract][Full Text] [Related]
2. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
3. Patients with ACVR1
Kou S; De Cunto C; Baujat G; Wentworth KL; Grogan DR; Brown MA; Di Rocco M; Keen R; Al Mukaddam M; le Quan Sang KH; Masharani U; Kaplan FS; Pignolo RJ; Hsiao EC
Orphanet J Rare Dis; 2020 Jul; 15(1):193. PubMed ID: 32727600
[TBL] [Abstract][Full Text] [Related]
4. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva.
Williams E; Bagarova J; Kerr G; Xia DD; Place ES; Dey D; Shen Y; Bocobo GA; Mohedas AH; Huang X; Sanderson PE; Lee A; Zheng W; Economides AN; Smith JC; Yu PB; Bullock AN
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33705358
[TBL] [Abstract][Full Text] [Related]
5. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
6. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
[TBL] [Abstract][Full Text] [Related]
7. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
8. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.
Pignolo RJ; Baujat G; Brown MA; De Cunto C; Di Rocco M; Hsiao EC; Keen R; Al Mukaddam M; Sang KLQ; Wilson A; White B; Grogan DR; Kaplan FS
Orphanet J Rare Dis; 2019 May; 14(1):98. PubMed ID: 31053156
[TBL] [Abstract][Full Text] [Related]
9. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.
Lindborg CM; Al Mukaddam M; Baujat G; Cho TJ; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao EC; Morhart R; de Ruiter R; Scott C; Seemann P; Szczepanek M; Tabarkiewicz J; Pignolo RJ; Kaplan FS
Clin Orthop Relat Res; 2023 Dec; 481(12):2447-2458. PubMed ID: 37156007
[TBL] [Abstract][Full Text] [Related]
10. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
11. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
[TBL] [Abstract][Full Text] [Related]
12. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
[TBL] [Abstract][Full Text] [Related]
13. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
[TBL] [Abstract][Full Text] [Related]
14. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
Wang H; De Cunto CL; Pignolo RJ; Kaplan FS
Bone; 2021 Aug; 149():115978. PubMed ID: 33915334
[TBL] [Abstract][Full Text] [Related]
15. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
16. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
17. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
18. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Di Rocco M; Forleo-Neto E; Pignolo RJ; Keen R; Orcel P; Funck-Brentano T; Roux C; Kolta S; Madeo A; Bubbear JS; Tabarkiewicz J; Szczepanek M; Bachiller-Corral J; Cheung AM; Dahir KM; Botman E; Raijmakers PG; Al Mukaddam M; Tile L; Portal-Celhay C; Sarkar N; Hou P; Musser BJ; Boyapati A; Mohammadi K; Mellis SJ; Rankin AJ; Economides AN; Trotter DG; Herman GA; O'Meara SJ; DelGizzi R; Weinreich DM; Yancopoulos GD; Eekhoff EMW; Kaplan FS
Nat Med; 2023 Oct; 29(10):2615-2624. PubMed ID: 37770652
[TBL] [Abstract][Full Text] [Related]
19. A fibrodysplasia ossificans progressiva patient with a rare missense mutation in ACVR1 detected on
Ni H; Tang S; Zhang Y
Joint Bone Spine; 2024 Mar; 91(2):105682. PubMed ID: 38159793
[TBL] [Abstract][Full Text] [Related]
20. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
